GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Cyclically Adjusted Price-to-FCF

AVANIR Pharmaceuticals (FRA:AV2B) Cyclically Adjusted Price-to-FCF : (As of May. 17, 2024)


View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


AVANIR Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AVANIR Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

AVANIR Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AVANIR Pharmaceuticals Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AVANIR Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVANIR Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



AVANIR Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AVANIR Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2014 is calculated as:

For example, AVANIR Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2014 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2014 (Change)*Current CPI (Sep. 2014)
=-0.034/100.4278*100.4278
=-0.034

Current CPI (Sep. 2014) = 100.4278.

AVANIR Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200412 -0.200 80.290 -0.250
200503 -0.295 81.555 -0.363
200506 -0.229 82.062 -0.280
200509 0.072 83.876 0.086
200512 -0.385 83.032 -0.466
200603 -0.148 84.298 -0.176
200606 -0.263 85.606 -0.309
200609 -0.335 85.606 -0.393
200612 -0.419 85.142 -0.494
200703 -0.275 86.640 -0.319
200706 -0.090 87.906 -0.103
200709 -0.116 87.964 -0.132
200712 -0.066 88.616 -0.075
200803 -0.076 90.090 -0.085
200806 -0.029 92.320 -0.032
200809 -0.039 92.307 -0.042
200812 -0.054 88.697 -0.061
200903 -0.054 89.744 -0.060
200906 -0.040 91.003 -0.044
200909 -0.040 91.120 -0.044
200912 -0.054 91.111 -0.060
201003 -0.041 91.821 -0.045
201006 -0.051 91.962 -0.056
201009 -0.058 92.162 -0.063
201012 -0.100 92.474 -0.109
201103 -0.082 94.283 -0.087
201106 -0.084 95.235 -0.089
201109 -0.088 95.727 -0.092
201112 -0.105 95.213 -0.111
201203 -0.078 96.783 -0.081
201206 -0.088 96.819 -0.091
201209 -0.069 97.633 -0.071
201212 -0.072 96.871 -0.075
201303 -0.054 98.209 -0.055
201306 -0.068 98.518 -0.069
201309 -0.153 98.790 -0.156
201312 -0.053 98.326 -0.054
201403 -0.078 99.695 -0.079
201406 -0.072 100.560 -0.072
201409 -0.034 100.428 -0.034

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AVANIR Pharmaceuticals  (FRA:AV2B) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AVANIR Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines